Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor

AIMS: Navoximod (GDC‐0919, NLG‐919) is a small molecule inhibitor of indoleamine‐2,3‐dioxygenase 1 (IDO1), developed to treat the acquired immune tolerance associated with cancer. The primary objectives of this study were to assess navoximod's absolute bioavailability (aBA), determine the mass...

Full description

Saved in:
Bibliographic Details
Published in:Br J Clin Pharmacol
Main Authors: Ma, Shuguang, Suchomel, Julia, Yanez, Evelyn, Yost, Edward, Liang, Xiaorong, Zhu, Rui, Le, Hoa, Siebers, Nicholas, Joas, Lori, Morley, Roland, Royer‐Joo, Stephanie, Pirzkall, Andrea, Salphati, Laurent, Ware, Joseph A., Morrissey, Kari M.
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2019
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6624388/
https://ncbi.nlm.nih.gov/pubmed/30973970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13961
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items